Advertisement

Drug Shortages and Their Impact on Patients and Health Care Systems—How Can Systemic and Organizational Frameworks Help to Prevent or Mitigate Them?

  • Phung Hoang Truong
  • Celia Cathérine Rothe
  • Tomasz BochenekEmail author
Chapter
Part of the Lecture Notes in Logistics book series (LNLO)

Abstract

Shortages of medicines have been reported worldwide, becoming a public health problem in many countries in recent years. They negatively impact on treatment outcomes, quality and efficiency of patient care, as well as that they pose organizational, managerial and financial burdens on health care facilities and generally—health care systems. Health and well-being of patients is and should always be the top priority for health care decision-makers; however, the variety of vested interests of different stakeholders of the pharmaceutical market makes coping with and preventing drug shortages a very difficult task. Characteristics of drug shortages vary across countries, but several lessons can be drawn based on a collective international experience. The complex nature of drug shortages necessitates an interdisciplinary approach, international collaboration and the application of experience from different scientific spheres. This chapter discusses dimensions of the impact that drug shortages have on patients’ health and well-being, and health care systems. Various measures, systemic and organizational frameworks aimed to prevent or mitigate drug shortages are also discussed, as well as their role in diminishing the impact of drug shortages. The adopted methodology included a non-systematic review of the scientific literature and documents published by organizations active in the health care sector and pharmaceutical markets. This was supplemented by gathering additional information from selected health care system stakeholders and analysts who are dealing with the problem of drug shortages in different countries.

Keywords

Drug shortages Health care quality Health care costs Health care system Health care impact Financial impact 

References

  1. Alevizakos, M., Detsis, M., Grigoras, C. A., Machan, J. T., & Mylonakis, E. (2016). The impact of shortages on medication prices: Implications for shortage prevention. Drugs, 76(16), 1551–1558.  https://doi.org/10.1007/s40265-016-0651-7.CrossRefPubMedGoogle Scholar
  2. American Society of Health-System Pharmacists. (n.d.). Current drug shortages.Google Scholar
  3. American Society of Health-System Pharmacists. (2009). ASHP guidelines on managing drug product shortages in hospitals and health systems, pp. 101–107.Google Scholar
  4. Baldini, G., et al. (2017). Enforcers and brand owners’ empowerment in the fight against counterfeiting.  https://doi.org/10.2760/135671.
  5. Barber, K. E., Bell, A. M., Travis King, S., Parham, J. J., & Stover, K. R. (2016). Impact of piperacillin-tazobactam shortage on meropenem use: Implications for antimicrobial stewardship programs. Brazilian Journal of Infectious Diseases, 20(6), 631–634.  https://doi.org/10.1016/j.bjid.2016.08.001.CrossRefPubMedGoogle Scholar
  6. BASG. (2018). Vertriebseinschränkungen von Arzneispezialitäten. Retrieved November 10, 2018, from https://medicineshortage.basg.gv.at/vertriebseinschraenkungen/faces/main?_afrLoop=4218347593426027&_afrWindowMode=0&_adf.ctrl-state=pm7603j4i_4.
  7. Bible, J. R., Evans, D. C., Payne, B., & Mostafavifar, L. (2014). Impact of drug shortages on patients receiving parenteral nutrition after laparotomy. Journal of Parenteral and Enteral Nutrition, 38(6), 65S–71S.  https://doi.org/10.1177/0148607114550317.CrossRefPubMedGoogle Scholar
  8. Bochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., et al. (2018). Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 european and western asian countries. Frontiers in Pharmacology. Retrieved, from https://www.frontiersin.org/article/10.3389/fphar.2017.00942.
  9. Casassus, B. (2015). Europe urged to take action on drug shortages. The Lancet, 385(9975), 1279–1280.  https://doi.org/10.1016/S0140-6736(15)60667-5.CrossRefGoogle Scholar
  10. Caulder, C., Mehta, B., Bookstaver, P., Sims, L., Stevenson, B., & South Carolina Society of Health-Sy. (2015). Impact of Drug Shortages on Health System Pharmacies in the Southeastern United States. Hospital Pharmacy, 50(4), 279–286.  https://doi.org/10.1310/hpj5004-279.
  11. Coombes, R. (2018). Brexit: The clock is ticking. BMJ, 362, k4057.  https://doi.org/10.1136/bmj.k4057.CrossRefGoogle Scholar
  12. Culliton, B. J. (1976). Penicillin G: Suddenly a shortage. Science, 191(4232), 1157.  https://doi.org/10.1126/science.191.4232.1157.CrossRefPubMedGoogle Scholar
  13. De Weerdt, E., Simoens, S., Casteels, M., & Huys, I. (2015a). Toward a European definition for a drug shortage: A qualitative study. Frontiers in Pharmacology, 6, 1–9.  https://doi.org/10.3389/fphar.2015.00253.CrossRefGoogle Scholar
  14. De Weerdt, E., Simoens, S., Hombroeckx, L., Casteels, M., & Huys, I. (2015b). Causes of drug shortages in the legal pharmaceutical framework. Regulatory Toxicology and Pharmacology, 71(2), 251–258.  https://doi.org/10.1016/j.yrtph.2015.01.005.CrossRefPubMedGoogle Scholar
  15. De Weerdt, E., De Rijdt, T., Simoens, S., Casteels, M., & Huys, I. (2017). Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study. PLoS ONE, 12(3), 1–15.  https://doi.org/10.1371/journal.pone.0174556.CrossRefGoogle Scholar
  16. Dill, S., & Ahn, J. (2014). Drug shortages in developed countries - Reasons, therapeutic consequences, and handling. European Journal of Clinical Pharmacology, 70(12), 1405–1412.  https://doi.org/10.1007/s00228-014-1747-1.CrossRefPubMedGoogle Scholar
  17. EC. (2017). Communication from the commission to the European parliament, the council and the European economic and social committee - a balanced IP enforcement system responding to today’s societal challenges, (COM(2017) 707).Google Scholar
  18. EMA. (2018a). EU regulatory network reflection paper on the availability of authorised medicinal products for human and veterinary use, 44, 1–16. Retrieved, from https://www.ema.europa.eu/documents/other/eu-regulatory-network-reflection-paper-availability-authorised-medicinal-products-human-veterinary_en.pdf.
  19. EMA. (2018b). Shortages catalogue| European medicines agency. Retrieved November 10, 2018, from https://www.ema.europa.eu/en/human-regulatory/post-authorisation/medicine-shortages/shortages-catalogue.
  20. European Association of Hospital Pharmacists (EAHP) secretariat. (2014). Medicines shortages in European hospitals. European Journal of Hospital Pharmacy, 1–46.Google Scholar
  21. Fox, E. R. (2015). New Trends in Drug Shortages. Pharmacy Purchasing & Products Magazine, 4.Google Scholar
  22. Fox, E. R., & Tyler, L. S. (2003). Managing drug shortages: Seven years’ experience at one health system. American Journal of Health-System Pharmacy, 60(3), 245–253. Retrieved, from https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038107428&partnerID=40&md5=f5147601fba9c76bbfd9630a3a557fe7.
  23. Goldsack, J. C., Reilly, C., Bush, C., McElligott, S., Bristol, M. N., Motanya, U. N., et al. (2014). Impact of shortages of injectable oncology drugs on patient care. American Journal of Health-System Pharmacy, 71(7), 571–578.  https://doi.org/10.2146/ajhp130569.
  24. Hakim, P., Georgitseas, N., Degun, R., & Suponcic, S. (2015). Brexit and Grexit: Implications for the pharmaceutical industry. Value in Health, 18(7), A571.  https://doi.org/10.1016/j.jval.2015.09.1885.CrossRefGoogle Scholar
  25. Canada, Health. (2015). Drug shortages in canada. Drugs and Health Products, 17, 1–16.Google Scholar
  26. Health Products Regulatory Authority. (2016). Health Products Regulatory Authority Strategic Plan 2016–2020.Google Scholar
  27. Heiskanen, K., Ahonen, R., Karttunen, P., Kanerva, R., & Timonen, J. (2015). Medicine shortages - a study of community pharmacies in Finland. Health Policy, 119(2), 232–238.  https://doi.org/10.1016/j.healthpol.2014.11.001.CrossRefPubMedGoogle Scholar
  28. Hughes, K. M., Goswami, E. S., & Morris, J. L. (2015). Impact of a drug shortage on medication errors and clinical outcomes in the pediatric intensive care unit. The Journal of Pediatric Pharmacology and Therapeutics, 20(6), 453–461.  https://doi.org/10.5863/1551-6776-20.6.453.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Jensen, V., Kimzey, L. M., & Goldberger, M. J. (2002). FDA’s role in responding to drug shortages. American Journal of Health-System Pharmacy, 59(15), 1423–1425.CrossRefGoogle Scholar
  30. Kaakeh, R., Sweet, B. V., Reilly, C., Bush, C., DeLoach, S., Higgins, B., et al. (2011). Impact of drug shortages on U.S. health systems. American Journal of Health-System Pharmacy, 68(19), 1811–1819.  https://doi.org/10.2146/ajhp110210.CrossRefPubMedGoogle Scholar
  31. Kempe, A., Daley, M. F., Stokley, S., Crane, L. A., Beaty, B. L., Barrow, J., et al. (2007). Impact of a severe influenza vaccine shortage on primary care practice. American Journal of Preventive Medicine, 33(6), 486–491.  https://doi.org/10.1016/j.amepre.2007.07.038.CrossRefPubMedGoogle Scholar
  32. Kontturi, A., Santiago, B., Tebruegge, M., von Both, U., Salo, E., Ritz, N., et al. (2016). The impact of Bacille Calmette-Guérin shortage on immunisation practice and policies in Europe – a paediatric tuberculosis network European trials group (ptbnet) survey. Tuberculosis, 101, 125–129.  https://doi.org/10.1016/j.tube.2016.08.005.CrossRefPubMedGoogle Scholar
  33. Mackey, T. K., & Annaloro, J. (2018). ‘Bioexit’: Navigating the policy and regulatory pathways for the biotechnology industry in a post-Brexit landscape. Drug Discovery Today, 23(7), 1324–1327.  https://doi.org/10.1016/J.DRUDIS.2018.02.013.CrossRefPubMedGoogle Scholar
  34. McBride, A., Holle, L. M., Westendorf, C., Sidebottom, M., Griffith, N., Muller, R. J., et al. (2013). National survey on the effect of oncology drug shortages on cancer care. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 70(7), 609–617.CrossRefGoogle Scholar
  35. McLaughlin, M., Kotis, D., Thomson, K., Harrison, M., Fennessy, G., Postelnick, M., et al. (2013). Effects on patient care caused by drug shortages: A survey. Journal of Managed Care Pharmacy, 19(9), 783–788.  https://doi.org/10.18553/jmcp.2013.19.9.783.CrossRefPubMedGoogle Scholar
  36. Mehrjerdi, Y. Z. (2015). RFID Role in Efficient Management of Healthcare Systems : A System Thinking.Google Scholar
  37. Morrison, A. (2011). Drug Supply Disruptions. Environmental Scans. Ottawa.Google Scholar
  38. Murphy, D., Reaman, G., & Jensen, C. V. (2014). Pediatric oncology drug shortages: A multifaceted problem. Pediatrics, 133(3), e728–e729.  https://doi.org/10.1542/peds.2013-4018.CrossRefPubMedGoogle Scholar
  39. Office of the Assistant Secretary for Planning and Evaluation; Office of Science and Data Policy - U.S. Department of Health and Human Service. (2011). Economic analysis of the causes of drug shortages. In National Drug Shortages: Trends and FDA Response (pp. 51–74). Washington D.C.: Nova Science Publishers, Inc.Google Scholar
  40. Pauwels, K., Huys, I., Casteels, M., & Simoens, S. (2014). Drug shortages in European countries: A trade-off between market attractiveness and cost containment? BMC Health Services Research, 14(1), 438.  https://doi.org/10.1186/1472-6963-14-438.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Pauwels, K., Simoens, S., Casteels, M., & Huys, I. (2015). Insights into european drug shortages: A survey of hospital pharmacists. PLoS ONE, 10(3), 1–13.  https://doi.org/10.1371/journal.pone.0119322.CrossRefGoogle Scholar
  42. Pejic Bach, M., Zoroja, J., & Loupis, M. (2016). RFID usage in European enterprises and its relation to competitiveness: Cluster analysis approach, 8, 1–11.  https://doi.org/10.1177/1847979016685093.CrossRefGoogle Scholar
  43. Schwartzberg, E., Ainbinder, D., Vishkauzan, A., & Gamzu, R. (2017). Drug shortages in Israel: Regulatory perspectives, challenges and solutions. Israel Journal of Health Policy Research, 6(1), 17.  https://doi.org/10.1186/s13584-017-0140-9.CrossRefPubMedPubMedCentralGoogle Scholar
  44. Stolar, M. H. (1976). Drug shortages. Science, 192(4235), 94.  https://doi.org/10.1126/science.192.4235.94.CrossRefPubMedGoogle Scholar
  45. Tan, Y. X., Moles, R. J., & Chaar, B. B. (2016). Medicine shortages in Australia: Causes, impact and management strategies in the community setting. International Journal of Clinical Pharmacy, 38(5), 1133–1141.  https://doi.org/10.1007/s11096-016-0342-1.CrossRefPubMedGoogle Scholar
  46. U.S. Food and Drug Administration. (2011). A review of FDA’ s approach to medical product shortages. Drug shortage report. Retrieved, from https://www.asahq.org/~/media/sites/asahq/files/public/advocacy/federalactivities/regulatory-activities/fdarxshortagereport1.pdf?la=en.
  47. UK Department of Health, & Association of the British Pharmaceutical Industry. (2007). Guidance notification and management of medicines shortages: ABPI.Google Scholar
  48. United States Government Accountability Office Report. (2014, February). Drug shortages. Public health threat continues, despite efforts to help ensure product availability, 94. Retrieved, from http://www.gao.gov/assets/670/660785.pdf.
  49. Ventola, C. L. (2011). The drug shortage crisis in the United States: Causes, impact, and management strategies. P & T : A Peer-Reviewed Journal for Formulary Management, 36(11), 740–757. Retrieved, from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3278171&tool=pmcentrez&rendertype=abstract.
  50. World health organisation (WHO). (2016, October). Meeting report: Technical definitions of shortages and stockouts of medicines and vaccines. World Health Organization.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Phung Hoang Truong
    • 1
  • Celia Cathérine Rothe
    • 1
  • Tomasz Bochenek
    • 1
    Email author
  1. 1.Faculty of Health SciencesJagiellonian University Medical CollegeKrakówPoland

Personalised recommendations